Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Dipti Doshi, MD

Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
Member of the Healthcare Council

Dipti Doshi, MD, is a board certified Rheumatologist at Health Care Partners Medical group, California. Dr. Doshi is also board certified in Internal Medicine. Her special interests are in rheumatoid arthritis, lupus, pain-related to scleroderma, fibromyalgia, and osteoarthritis. Dr. Doshi is interested in clinical research trials of any new drug entering the market for rheumatological diseases and is also interested in reading about new drugs which might be a miracle cure for patients' disease in the future. She has done research for over two years on scleroderma complications and related organ involvement with progression of disease activity. She also participated in clinical trials and research related to new drugs in phase II or III for Rheumatoid arthritis and osteoarthritis in the past. Previously, she has worked as full time rheumatologist with Kaiser Permanente and Methodist hospital, Illinois. (This is me - Update Profile)


Employment History
2008 - present Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
2007 - 2008 Rheumatologist
Kaiser Permanente Medical Group
2005 - 2007 Rheumatologist
METHODIST MEDICAL CENTER OF ILLINOIS,
2001 - 2005 Rheumatology fellow
University of Texas Medical Branch At Galveston

GLG Study Groups with Dipti Doshi, MD(?)

View All Study Groups with Dipti Doshi, MD

GLG NewsSM Analyses by Dipti Doshi, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
TRU-015 and SBI-087 both trubion's product both strong products with Different MOA , B cell depletion. | 05-01-2008
Analysis of: Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis | www.pipelinereview.com
Author: Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab,...

Phase 2 study showing that a 1mg treatment with Adlea(TM) effective for 12 week persistant pain in OA patients | 07-04-2007
Analysis of: Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee | www.pipelinereview.com
Author: Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Pharmacokinetic studies of Adlea showed that when it is locally administered to the site of pain, there appears to be limited systemic exposure. Its short duration of systemic exposure (hours) relative to the long duration of analgesia (12 weeks) resulting from a single treatment course of Adlea is...

Roche's market share will go up . | 06-18-2007
Analysis of: New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis | pharmalive.com
Author: Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Very important new treatment emerging in field of rheumatoid arthritis along with other drugs in pipeline. IL-6 receptor blocker. New Mechanism of action. Has positive priliminary endpoint results at 24 week study for RA compared to DMARD therapy alone.

SRV in non responders | 05-28-2007
Analysis of: "Triple Anti-HCV Drug Therapy for Nonresponders to Peginterferon/Ribavirin: Interferon Gamma (Actimmune) + Ribavirin + Pegasys or Infergen: A Pilot Study" | www.natap.org
Author: Dipti Doshi, MD, Rheumatologist, HEALTHCARE PARTNERS MEDICAL GROUP

Very nice article. Although sample size seemed very less, avaialble results look very promising. Particularly in contrast of Leevy study. Only concern is of side-effects. Would make things clear on further study with the same drug

GLG InstituteSM Seminars with Dipti Doshi, MD(?)

 
Dipti Doshi, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Dipti Doshi, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics